The presented case report concerns a 62-year-old male patient who was admitted to the rheumatology department with a fever, shoulder and hip joint pain, significant limitation of movement in these joints and general weakness. Laboratory test revealed increase of inflammatory parameters, as ESR and C-reactive protein, rheumatoid factor and ACPA antibodies were absent. In the course of diagnostics, infections and cancer were excluded. The patient met the classification criteria for polymyalgia rheumatica. Polymyalgia rheumatica is not a rare disease, but the number of elderly people in the world continues to increase, and we can assume that the prevalence of this disease will increase in the coming years. At suspicion on polymyalgia rheumatica, it is necessary to exclude other rheumatic diseases, infections and malignant neoplasms. The authors also presented which diseases should be considered in the differential diagnosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052374 | PMC |
http://dx.doi.org/10.5114/reum.2018.76906 | DOI Listing |
Rev Med Suisse
January 2025
Service de rhumatologie, HFR Fribourg, 1708 Fribourg.
In 2024, CD19-CAR T cells are ubiquitous in rheumatology, with incredible therapeutic results in cases of severe and refractory disease. This major advance confirms the interest of the B lymphocyte as a therapeutic target, and also suggests the real possibility of a drug-free remission, at the price of minor and minimal side effects for the time being. However, the necessary perspective is still lacking for a therapy that remains out of reach because of its price.
View Article and Find Full Text PDFArthritis Rheumatol
January 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Rheumatology and Clinical Immunology, 10117, Berlin, Germany.
Objective: An unmet need exists for glucocorticoid-sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody-drug conjugate ABBV-154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV-154 versus placebo in patients with glucocorticoid-dependent PMR.
View Article and Find Full Text PDFJ Ultrasound
January 2025
Department of Physical Medicine and Rehabilitation, University of Health Science Fatih Sultan Mehmet Training and Research Hospital, E5 Karayolu Üzeri, İçerenköy-Ataşehir, 34752, Istanbul, Turkey.
Shoulder Injury Related to Vaccine Administration (SIRVA) is a complication caused by improperly administered vaccinations. It triggers an inflammatory cascade that damages shoulder structures, resulting in prolonged shoulder pain and restricted range of motion. Common diagnoses in SIRVA patients include shoulder bursitis (all classified as subacromial bursitis), adhesive capsulitis, and rotator cuff injuries such as tears or tendinopathy.
View Article and Find Full Text PDFMod Rheumatol
January 2025
Medical Affairs Department, Asahi Kasei Pharma Corporation, Tokyo, Japan.
Objectives: This study aimed to describe the characteristics, inflammatory markers as surrogates for disease activity, and treatment of patients with polymyalgia rheumatica (PMR) in Japan.
Methods: This cohort study analysed the data of 373 patients with PMR retrieved from an electronic medical records database in Japan. Patients were classified into quartiles, based on the daily glucocorticoid dose over the initial 90 days of treatment (Q1-Q4).
Lancet Rheumatol
January 2025
Department of Rheumatology, Hospital of Brunico, Teaching Hospital of the Paracelsius Medical University, Brunico 39031, Italy; Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Medical University, Graz, Austria. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!